» Articles » PMID: 21352195

New Advances in Pharmacotherapy for Early Psychosis

Overview
Specialty Psychiatry
Date 2011 Mar 1
PMID 21352195
Citations 3
Authors
Affiliations
Soon will be listed here.
Abstract

Aim: This review examines the use of antipsychotic medication during the early years of psychosis.

Methods: A selective literature review was conducted.

Results: The early years of schizophrenia represent a critical period for intervention. Importantly, first-episode patients differ from those with chronic schizophrenia in several important respects. While treatment response to antipsychotic medication is better, the risk of relapse is also higher. While both first- and second-generation antipsychotics are very effective in reducing symptoms, there are tolerability and some efficacy advantages for the second-generation antipsychotics in first-episode psychosis. Poor medication adherence is a significant problem in early psychosis that is linked to relapse and poses a major barrier to optimizing outcomes. Treatment strategies should focus on, among other things, improving antipsychotic medication adherence.

Conclusions: The early years of psychosis offer the best opportunity for achieving optimal outcomes. Maintaining symptomatic remission is central to achieving functional recovery.

Citing Articles

Randomized open-label study of second-generation antipsychotics for the treatment of schizophrenia: 104-week final results of the JUMPs study assessing treatment discontinuation, remission, and social functioning.

Ishigooka J, Nakagome K, Ohmori T, Iwata N, Inada K, Iga J BMC Psychiatry. 2024; 24(1):600.

PMID: 39237918 PMC: 11376064. DOI: 10.1186/s12888-024-06031-4.


Rate of and time to symptomatic remission in first-episode psychosis in Northern Malawi: A STROBE-compliant article.

Kaminga A, Dai W, Liu A, Myaba J, Banda R, Wen S Medicine (Baltimore). 2018; 97(45):e13078.

PMID: 30407306 PMC: 6250544. DOI: 10.1097/MD.0000000000013078.


Patients' and clinicians' attitude towards long-acting depot antipsychotics in subjects with a first episode of psychosis.

Kirschner M, Theodoridou A, Fusar-Poli P, Kaiser S, Jager M Ther Adv Psychopharmacol. 2013; 3(2):89-99.

PMID: 24167680 PMC: 3805393. DOI: 10.1177/2045125312464106.